These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 34950321)
21. Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control]). Parkash R; Wells GA; Sapp JL; Healey JS; Tardif JC; Greiss I; Rivard L; Roux JF; Gula L; Nault I; Novak P; Birnie D; Ha A; Wilton SB; Mangat I; Gray C; Gardner M; Tang ASL Circulation; 2017 May; 135(19):1788-1798. PubMed ID: 28228428 [TBL] [Abstract][Full Text] [Related]
22. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. Lv J; Neal B; Ehteshami P; Ninomiya T; Woodward M; Rodgers A; Wang H; MacMahon S; Turnbull F; Hillis G; Chalmers J; Perkovic V PLoS Med; 2012; 9(8):e1001293. PubMed ID: 22927798 [TBL] [Abstract][Full Text] [Related]
23. Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: A meta-analysis. Wang J; Chen Y; Xu W; Lu N; Cao J; Yu S PLoS One; 2019; 14(4):e0215362. PubMed ID: 30978254 [TBL] [Abstract][Full Text] [Related]
24. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension. Wong GW; Laugerotte A; Wright JM Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007449. PubMed ID: 26306578 [TBL] [Abstract][Full Text] [Related]
25. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials. Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268 [TBL] [Abstract][Full Text] [Related]
26. Free versus Fixed Combination Antihypertensive Therapy for Essential Arterial Hypertension: A Systematic Review and Meta-Analysis. Mallat SG; Tanios BY; Itani HS; Lotfi T; Akl EA PLoS One; 2016; 11(8):e0161285. PubMed ID: 27548060 [TBL] [Abstract][Full Text] [Related]
27. Effect of intensive blood pressure lowering on left atrial remodeling in the SPRINT. Kamel H; Rahman AF; O'Neal WT; Lewis CE; Soliman EZ Hypertens Res; 2021 Oct; 44(10):1326-1331. PubMed ID: 34363050 [TBL] [Abstract][Full Text] [Related]
28. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. Thomopoulos C; Parati G; Zanchetti A J Hypertens; 2016 Apr; 34(4):613-22. PubMed ID: 26848994 [TBL] [Abstract][Full Text] [Related]
29. What Is the Ideal Blood Pressure Threshold for the Prevention of Atrial Fibrillation in Elderly General Population? Park YJ; Yang PS; Yu HT; Kim TH; Jang E; Uhm JS; Pak HN; Lee MH; Lip GYH; Joung B J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32947828 [TBL] [Abstract][Full Text] [Related]
30. Incidence and Implications of Atrial Fibrillation/Flutter in Hypertension: Insights From the SPRINT Trial. Parcha V; Patel N; Kalra R; Kim J; Gutiérrez OM; Arora G; Arora P Hypertension; 2020 Jun; 75(6):1483-1490. PubMed ID: 32362231 [TBL] [Abstract][Full Text] [Related]
31. Pharmacotherapy for hyperuricemia in hypertensive patients. Gois PH; Souza ER Cochrane Database Syst Rev; 2013 Jan; (1):CD008652. PubMed ID: 23440832 [TBL] [Abstract][Full Text] [Related]
32. Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial). Patel KK; Arnold SV; Chan PS; Tang Y; Pokharel Y; Jones PG; Spertus JA Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28373269 [TBL] [Abstract][Full Text] [Related]
33. Measurement reliability of automated oscillometric blood pressure monitor in the elderly with atrial fibrillation: a systematic review and meta-analysis. Park SH; Choi YK Blood Press Monit; 2020 Feb; 25(1):2-12. PubMed ID: 31714346 [TBL] [Abstract][Full Text] [Related]
37. Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2 × 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment. Huang Y; Sharma VK; Robinson T; Lindley RI; Chen X; Kim JS; Lavados P; Olavarría V; Arima H; Fuentes S; Nguyen HT; Lee TH; Parsons MW; Levi C; Demchuk AM; Bath PM; Broderick JP; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Pandian J; Ricci S; Stapf C; Woodward M; Wang J; Chalmers J; Anderson CS; Int J Stroke; 2015 Jul; 10(5):778-88. PubMed ID: 25832995 [TBL] [Abstract][Full Text] [Related]
38. Treatment of Hypertension: Which Goal for Which Patient? Jarraya F Adv Exp Med Biol; 2017; 956():117-127. PubMed ID: 27722961 [TBL] [Abstract][Full Text] [Related]
39. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Tandon N; Ali MK; Narayan KM Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193 [TBL] [Abstract][Full Text] [Related]